Skip to content
value.today

Gilead Sciences, Inc.: financial analysis

Ratios worked out from 10 fiscal years of Gilead Sciences, Inc.'s statements, compared with 102 companies in Pharmaceutical.

Gilead Sciences, Inc. scorecard#

Passes 1 of the 6 checks that could be worked out. Fiscal year 2026; market cap of Oct 26, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median8.5×Price to book 8.5× against Pharmaceutical's median of 3.2×.
    • ✗Price to sales below its peers' median6.2×Price to sales 6.2× against Pharmaceutical's median of 3.5×.
    • ✗Free cash flow yield above 5%4.9%Free cash flow is 4.9% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'No revenue growth over three years on file.
  • Growthnot known
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitabilitynot known
    • –Profitable in the newest yearNo net income on file.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial healthnot known
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • ✓Dividend per share raised five years in a row10 yearsRaised 10 calendar years in a row (SEC dividends declared).
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec, wikidata), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Profitability#

Gilead Sciences, Inc.: profitability by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Gross margin—78.8%78.3%76.0%79.3%53.3%—
Operating margin—34.0%5.8%28.1%26.9%1.8%—
Net margin—28.9%1.7%20.9%16.8%-1.5%—
Return on equity—40.5%2.3%25.7%21.7%-0.9%—
Return on assets—14.4%0.8%9.0%7.0%-1.3%—
Return on invested capital—22.9%3.0%15.0%13.8%14.4%—

Growth#

Gilead Sciences, Inc.: growth by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Revenue growth—2.4%6.0%-0.6%-0.1%7.3%—
Revenue growth, 3 years a year—2.6%1.7%3.2%6.7%2.5%—
Revenue growth, 5 years a year—3.6%5.1%4.2%0.9%6.0%—
Net income growth——-91.5%23.4%-26.2%14.3%—
Earnings per share growth——-91.6%23.6%-26.2%12.4%—

Financial strength#

Gilead Sciences, Inc.: financial strength by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Debt to equity—1.10×1.38×1.09×1.19×0.66×—
Net debt—$17.4 B$16.7 B$18.9 B$19.8 B$188 M—
Interest cover———8.06×7.84×1.11×—
Current ratio—1.55×1.60×1.43×1.29×1.98×—
Equity share of assets—38.5%32.8%36.8%33.6%47.3%—

Cash#

Gilead Sciences, Inc.: cash by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Free cash flow—$9.5 B$10.3 B$7.4 B$8.3 B$8 M—
Free cash flow margin—32.1%35.8%27.4%30.6%6.0%—
Cash conversion—117.7%—141.3%197.6%136.7%—
Capital spending share of revenue—1.9%1.8%2.2%2.7%2.6%—

Shareholder returns#

Gilead Sciences, Inc.: shareholder returns by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Dividend payout—47.0%816.3%67.2%80.8%47.1%—
Change in share count—0.0%-0.2%-0.3%0.0%1.8%—

Efficiency#

Gilead Sciences, Inc.: efficiency by fiscal year
Fiscal yearTrend20262025202420232022Median of peersAhead of
Asset turnover—0.50×0.47×0.43×0.42×0.55×—

How each figure is worked out#

Gross margin
Gross profit as a share of revenue.
Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on equity
Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
Return on assets
Net income as a share of total assets (average of the year).
Return on invested capital
Operating income after tax, as a share of debt plus equity less cash (average of the year). The tax rate is the year's own: income tax over pre-tax income.
Revenue growth
Revenue against the year before.
Revenue growth, 3 years a year
The yearly rate that takes revenue of three years earlier to this year's.
Revenue growth, 5 years a year
The yearly rate that takes revenue of five years earlier to this year's.
Net income growth
Net income against the year before. Only when both years were profitable.
Earnings per share growth
Diluted earnings per share against the year before. Only when both were positive.
Debt to equity
Total debt divided by shareholders' equity. Not given when equity is negative.
Net debt
Total debt less cash. Negative means more cash than debt.
Interest cover
Operating income divided by the interest paid on debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Cash conversion
Cash from operations as a share of net income. Only when the year was profitable.
Capital spending share of revenue
Capital spending as a share of revenue.
Dividend payout
Dividends paid as a share of net income. Only when the year was profitable.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Gilead Sciences, Inc.'s statements: annual reports filed with the SEC; Wikidata. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 102 companies in Pharmaceutical that Gilead Sciences, Inc. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Gilead Sciences, Inc.